Regulatory updates (digest-only, lower relevance)
- (57) [regulations.gov] Importer of Controlled-Bright Green(2024-20083)DEA1426
- (57) [regulations.gov] Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429
- (57) [regulations.gov] Importer Controlled- Quagen Pharma (2024-11892) DEA1381
- (57) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I
- (52) [regulations.gov] Importer Controlled-VA Cooperative (2024-11795) DEA1374
- (45) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I
- (35) [regulations.gov] Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
- (32) [regulations.gov] Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)
- (15) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)
- (7) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)
- (2) [regulations.gov] Definition of Engaged in the Business as a Dealer in Firearms
Digest-Level Clinical Commentary
Clinical Reflection
These regulatory notices suggest ongoing DEA scrutiny of controlled substance importation pathways and scheduling classifications, which underscores the importance of remaining vigilant about the distinction between federally scheduled compounds and state-legal cannabis products in clinical practice. As cannabis medicine practitioners, we must recognize that regulatory ambiguity around cannabinoid derivatives and importation channels reinforces the need for evidence-based patient counseling grounded in established safety data rather than assumptions about legality or purity. These updates remind us that our prescribing and recommendation practices operate within a complex federal landscape that continues to evolve, requiring regular review of current regulations to protect both our patients and our licensing.
Clinical Perspective
These regulatory updates reflect ongoing DEA scrutiny of controlled substance importation and scheduling classifications, particularly around synthetic compounds and their precursors. Clinicians should remain aware that evolving DEA scheduling decisions may impact the availability and legal status of substances used in research or clinical settings, requiring periodic review of institutional compliance protocols. The continued regulatory activity in this space underscores the importance of maintaining current knowledge of controlled substance classifications relevant to one’s practice or research.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: